Shopping Cart
Remove All
Your shopping cart is currently empty
Panobacumab (Alias: KBPA101, KBPA 101)
Catalog No. T76755 Copy Product Info
🥰Excellent
Panobacumab (KBPA101) is a fully humanised monoclonal antibody targeting Pseudomonas aeruginosa, specifically targeting the O-polysaccharide (OPS) component of the bacterial outer membrane LPS. It is effective against certain drug-resistant strains of P. aeruginosa, reduces pulmonary inflammation, and enhances the clearance of bacteria from the lungs by neutrophils.
Panobacumab
Copy Product Info🥰Excellent
Catalog No. T76755
Alias KBPA101, KBPA 101
Panobacumab (KBPA101) is a fully humanised monoclonal antibody targeting Pseudomonas aeruginosa, specifically targeting the O-polysaccharide (OPS) component of the bacterial outer membrane LPS. It is effective against certain drug-resistant strains of P. aeruginosa, reduces pulmonary inflammation, and enhances the clearance of bacteria from the lungs by neutrophils.
Panobacumab
Cas No. 885053-97-4
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $215 | - | In Stock | |
| 5 mg | $563 | - | In Stock | |
| 10 mg | $896 | - | In Stock |
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.8% (SDS-PAGE); 98.6% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Panobacumab (KBPA101) is a fully humanised monoclonal antibody targeting Pseudomonas aeruginosa, specifically targeting the O-polysaccharide (OPS) component of the bacterial outer membrane LPS. It is effective against certain drug-resistant strains of P. aeruginosa, reduces pulmonary inflammation, and enhances the clearance of bacteria from the lungs by neutrophils. |
| In vitro | Panobacumab (0.0001-100 ng/mL, 2 hours) specifically mediates complement-dependent phagocytosis of Pseudomonas aeruginosa serotype O11 with an IC50 of 0.16 ng/mL.[1] |
| In vivo | Methods: Panobacumab (0.005-0.4 mg/kg, intravenous injection, single dose) was used to treat a BALB/c mouse model of acute lung infection and its therapeutic efficacy was observed. Results: Panobacumab rapidly eliminated P. aeruginosa from the lungs and completely eliminated systemic P. aeruginosa from the spleen, whereas untreated mice still had viable bacteria 48 hours after infection and had milder lung pathology at 6 and 24 hours after infection. [1] |
| Synonyms | KBPA101, KBPA 101 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | P. aeruginosa |
| Molecular Weight | 146.09 kDa |
| Cas No. | 885053-97-4 |
| Isotype | Human IgM kappa |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Panobacumab | purchase Panobacumab | Panobacumab cost | order Panobacumab | Panobacumab in vivo | Panobacumab in vitro | Panobacumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.